iQure Pharma Secures $600K in Early Closing to Research Neuropathic Pain Therapies
Summary
Keiretsu and Business Angels Provide Funding to Support Research into Neuropathic Pain Compounds iQ-007 and iQ-008PRINCETON, N.J., Aug. 31, 2022 /PRNewswire/ -- iQure Pharma Inc. (iQure), a Princeton-based global biotech company, today confirmed completion of Early Closing as part of its Series A investment, which will support ongoing research into non-opioid therapeutics for neuropathic pain.iQure Pharm has secured over $600k of commitments to date and is supported by Keiretsu Mid-Atlantic, together with business angels associated with Keiretsus Accelerator Fund and the Keiretsu North-West chapter, to advance the preclinical development of iQures novel therapeutics iQ-007 and iQ-008. With the support of our investors and researchers, we are proud to be a part of the biotech community developing promising therapies of the future. "In particular, iQ-007 has demonstrated positive results in NIH ETSP tests, which show that the compound has the ability to treat pain, epilepsy, and potentially neurodegenerative diseases. Neuropathic pain is considered one of the most severe forms of chronic pain.A global biotech firm headquartered in Princeton, New Jersey, iQure Pharma is focused on the development of new therapeutics for neuropathic pain, epilepsy, and wider neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies.